We take a moment to thank everyone who has taken part, and to discuss the future of our community.
In a sharp-tongued argument, the political satirist argues that pharmaceutical companies and pharmacy benefit managers share the blame for runaway increases in drug pricing.
How Diamyd Medical, a T1D Exchange Diabetes Innovation Challenge semifinalist, is doggedly pursuing immunotherapy to halt the destruction of insulin-producing beta cells.
The designation will allow for expedited development of the pump system as the South Korean company prepares to submit it for FDA approval.
Several hundred participants take part in new effort to collect real-world data for type 1 diabetes research.
The proposed rule is an attempt to make sure Medicaid and Medicare recipients more directly benefit from drug discounts.
Glooko also recently announced a partnership to integrate with Novo Nordisk’s soon-to-be-released smart insulin pens.
The insulin maker also is asking European regulators for expanded Fiasp approval to treat the pediatric population.
A chef discusses his journey from low-carb skeptic to low-carb devotee and shares a favorite recipe.
The t:slim X2 is the first pump given the label of alternative controller-enabled (ACE) pump by the FDA.
Already a Member?
Learn more about the EOPancreas system under development.